Nuon Therapeutics Inc. Announces Positive Topline Results from a Phase 2a Study in Hyperuricemia

Published: Jun 16, 2010

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company’s lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.

Back to news